31.38
+6.70%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Agios Pharmaceuticals
From its filings with the US Securities and Exchange Commission
Agios Pharmaceuticals is based in Cambridge, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker AGIO. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $54.0m and a net loss of $412.8m. At that date it held total assets of $1.30bn and shareholders' equity of $1.19bn.
We are a commercial-stage biopharmaceutical company dedicated to redefining the future of rare disease treatment. Fueled by connections, we build trusted partnerships with communities, collaborating to develop and deliver innovative medicines with the potential to transform lives. With a foundation in hematology, we combine biological expertise with real-world insights to advance a growing pipeline of rare disease medicines that reflect the priorities of the people we serve.
The lead product candidate in our portfolio, mitapivat, is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. Mitapivat is approved in the United States by the U.S. Food and Drug Administration, or FDA, under the brand name AQVESME™ for the treatment of anemia in adults with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia and in Saudi Arabia under the brand name PYRUKYND® for the treatment of adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia. Mitapivat is also approved under the brand name PYRUKYND® in the United States by the FDA for the treatment of hemolytic anemia in adults with PK deficiency and in the European Union, or EU, and Great Britain for the treatment of PK deficiency in adults.
Quoted from its 10-K, filed 12 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 24 Jul 2013
- Employees
- 539
- Website
- agios.com ↗
- Head office
- 88 SIDNEY STREET, CAMBRIDGE, MA, 02139
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Dr. Jacqualyn FouseChairman of the Board, since 2017$443,781
- Mr. Brian GoffChief Executive Officer, Director, since 2022$6.8m
- Ms. Cecilia JonesChief Financial Officer$2.4m
- Mr. James BurnsChief Legal Officer$2.4m
- Dr. Sarah GheuensChief Medical Officer, Head - Research and Development$2.5m
- Ms. Tsveta MilanovaChief Commercial Officer$2.5m
- Mr. Krishnan ViswanadhanChief Corporate Development and Strategy Officer
- Ms. Kaye FosterLead Independent Director$448,781
- Dr. Jay BackstromDirector
- Dr. Rahul BallalIndependent Director$423,781
- Mr. Jeffrey CapelloIndependent Director$426,281
- Dr. Maykin HoIndependent Director$421,281
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 64
- Environment
- 50
- Social
- 99
- Governance
- 43
- Women in the workforce
- 60%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Agios Pharmaceuticals Inc has several strengths that contribute to its success in the pharmaceutical industry. These include:
Weaknesses
- Agios Pharmaceuticals Inc also faces certain weaknesses that may pose challenges to its business operations and growth. These weaknesses include:
Opportunities
- Agios Pharmaceuticals Inc can capitalize on various opportunities in the market to drive growth and success. These opportunities include:
Threats
- Agios Pharmaceuticals Inc faces several threats that may impact its business operations and market performance. These threats include:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.